Bio-Techne Makes Big Push Into Liquid Biopsy With Exosome Acquisition

Bio-Techne has reached an agreement to acquire Exosome Diagnostics, putting the firm in a stronger position in the emerging liquid biopsy and precision medicine spaces.

Bio-Techne Corp. is acquiring Exosome Diagnostics Inc. to complement its existing Advanced Cellular Diagnostics (ACD) business with Exosome's biofluid-based diagnostics, and to take advantage of the emerging precision-medicine trend.

"Exosome Diagnostic's technology is a game-changer, and positions Bio-Techne to be a leader in the rapidly-growing noninvasive liquid biopsy market," Bio-Techne CEO Charles Kummeth said June 25th

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business